Septerna outlines $157M IPO after entering the clinic with GPCR pipeline
GPCR drug developer Septerna plans to raise about $157 million in net proceeds from its proposed initial public offering, according to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
